SCHEMBL20535798

SCHEMBL20535798

Cc1cc(C(N)=O)ccc1-n1c2ccc(-n3ccnc3)cc2c2ccc(C(=O)O)cc21

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADH5 P11766 12/20 0.54
CYP2C19 P33261 1/20 0.54
MYC P01106 1/20 0.40
ESR1 P03372 1/20 0.40
ALOX15 P16050 1/20 0.40
PTPN7 P35236 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 1/20 0.40
BAZ2B Q9UIF8 1/20 0.40
CYP4Z1 Q86W10 1/20 0.39
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
TBXAS1 P24557 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30772955 1.00 ADH5 (0.54) ADH5CYP2C19MYCESR1ALOX15
SCHEMBL30772954 0.95 ADH5 (0.56) ADH5CYP2C19MYCESR1ALOX15
SCHEMBL20535770 0.95 ADH5 (0.56) ADH5CYP2C19MYCESR1ALOX15
SCHEMBL20535801 0.87 ADH5 (0.49) ADH5CYP2C19CYP3A4BAZ2BCYP4Z1
SCHEMBL30927852 0.87 ADH5 (0.49) ADH5CYP2C19CYP3A4BAZ2BCYP4Z1
SCHEMBL30772942 0.87 ADH5 (0.49) ADH5CYP2C19CYP3A4BAZ2BCYP4Z1
SCHEMBL22077233 0.87 ADH5 (0.61) ADH5CYP2C19CYP3A4BAZ2BMAPT
SCHEMBL25492037 0.82 ADH5 (0.48) ADH5CYP2C19CYP3A4BAZ2BMAPT
SCHEMBL20536594 0.82 ADH5 (0.52) ADH5CYP2C19CYP3A4BAZ2BCYP4Z1
SCHEMBL30772969 0.82 ADH5 (0.52) ADH5CYP2C19CYP3A4BAZ2BCYP4Z1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3609867-B1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS INC (US) 2024-05-15 EP disclosed
CN-110753683-B Carbazole compounds and methods of use thereof 吉斯诺治疗公司 2024-02-09 CN disclosed
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-11655244-B2 Carbazole compounds and methods of use thereof GSNO THERAPEUTICS, INC. (US) 2023-05-23 US disclosed
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS, INC. 2020-06-11 US disclosed
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSNO THERAPEUTICS, INC. 2020-06-11 US disclosed
EP-3609867-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF Saje Pharma, LLC (US) 2020-02-19 EP disclosed
CN-110753683-A Carbazole compounds and methods of use thereof 赛吉制药有限责任公司 2020-02-04 CN disclosed
WO-2018191418-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF SAJE PHARMA, LLC (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655244-B2 Carbazole compounds and methods of use thereof GSR, CBR3, CBR1 ADH5 93/4885CYP2C19 17/4885MYC 2050/4885
US-20200181129-A1 CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF GSR, CBR3, CBR1 ADH5 93/4885CYP2C19 17/4885MYC 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.